Noxxon Pharma starts dosing in Phase I/II trial of NOX-A12 for cancer
German firm Noxxon Pharma has started dosing patients in a Phase I/II clinical trial of NOX-A12 (olaptesed pegol) in combination with Keytruda (pembrolizumab) to treat metastatic colorectal and pancreatic cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Germany Health | Pancreas | Pancreatic Cancer | Pharmaceuticals